Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva CRL Response For Huntington’s Drug Targeted For September

Executive Summary

Teva is on track to respond to FDA’s complete response letter for deutetrabenazine by the end of September, with a potential for approval and launch in early 2017.

You may also be interested in...



Neurocrine Eyes June Launch Date For Valbenazine In Tardive Dyskinesia

Company no longer has to worry about a US FDA advisory committee review, which the agency cancelled. Launch preparations include hiring 140 sales reps.

Teva Preps For SD-809 Tardive Dyskinesia Filing By The End Of 2016

A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.

Keeping Track: Sandoz Erelzi Is Third Biosimilar To Clear FDA; Expanded Labels For Arzerra, Blincyto

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS118903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel